What's new ?

Pharma Nuclear Services
Sep 29, 2022
1 min read

EMA qualifies first Machine Learning based artificial Intelligence program for clinical trials...

This qualification is the first time a regulatory body has formally supported a machine learning-based method for reducing sample size in Phase II or III trials.

EMA Regulatory Procedural Guideline

Recent Posts

See All

Radiotracer targets key cancer biomarker for precision treatment

FDA Investigating Serious Risk of T-cell Malignancy

HOW IS AI HELPING TO ADVANCE THERANOSTICS?

Comments

bottom of page